Results of Axiom Mission 4’Suite Ride” are revealed, and the campaign is displayed in Times Square. Burjeel Holdings, a healthcare company based in Abu Dhabi, has declared its goal to launch the first diabetic astronaut into space, marking a revolutionary breakthrough for both space exploration and diabetes treatment. The statement expands on the first results of “Suite Ride,” a groundbreaking diabetes research study carried out in partnership with Axiom Space onboard the International Space Station (ISS) during Axiom Mission 4 (Ax-4). Space tests of diabetes tools
The study showed that common diabetic supplies, which are utilized by millions of people worldwide, can consistently deliver complete glucose tracking and insulin control in microgravity. The results promise new advancements in remote healthcare on Earth and in space, provide hope to more than 500 million people with diabetes, and open the door for astronauts with the disease. Tejpaul Bhatia, CEO of Axiom Space, and Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, attended the announcement ceremony at the Burjeel Institute for Global Health in New York. The results were previously presented at Times Square as well. Establishing a welcoming environment
During a panel discussion, Omran Sharaf, the Assistant Foreign Minister for Advanced Science and Technology of the United Arab Emirates, emphasized the significance of establishing an inclusive environment. Due to their genetic makeup, people from different parts of the world may need different types of therapies. The diverse data required to better inform science is produced by technologies such as the one recently tested in orbit.
A four-person crew tested the entire Suite Ride arrangement in microgravity for eighteen days during the Ax-4 mission. The study demonstrated that insulin pens functioned dependably in space and that continuous glucose monitors (CGMs) may provide accurate readings on par with monitoring conducted on Earth. The Galactic 07 mission successfully proved the use of commercial insulin pens in microgravity, and our results build on that achievement. “This goes beyond space exploration,” stated Gavin D’Elia, Axiom Space’s Global Head of Pharma. “It’s about encouraging individuals everywhere and showing them that their aspirations to explore space don’t stop with a diagnosis. We’re working together to advance remote healthcare, diabetes monitoring, and the possibility of flying the first astronaut with diabetes. Firsts in history
The first insulin pens to be flown into space, the first continuous glucose monitoring of crew members on board the ISS, and the first validation of glucose monitoring using several measuring techniques on the space station were all accomplished by Suite Ride. The results of the study have implications for improving underprivileged and isolated communities worldwide. In keeping with the UAE’s space aspirations, Burjeel Holdings started this research to advance space medicine. These discoveries will not only pave the way for astronauts with diabetes but also revolutionize the way we provide healthcare on Earth.
“We are developing new models of remote care from 250 miles above Earth to 25 miles offshore on oil rigs,” stated Dr. Mohammad Fityan, Chief Medical Officer at Burjeel Medical City and Clinical Lead of the Burjeel–Ax-4 Space Health Research.
